Jinghong Zhou

A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer

Jianming Xu, Huichuan Sun, Yi Li, 2021, Cancer.

Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: 
Safety, Efficacy, and Biomarkers

Jianxing He, Baorui Liu, Jian-hua Chang, 2022, The oncologist.

Surufatinib in combination with toripalimab in patients with advanced neuroendocrine carcinoma: Results from a multicenter, open-label, single-arm, phase II trial.

Ying Cheng, Jianming Xu, L. Shen, 2021 .

Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.

Weiguo Qing, Y. Sai, Yumin Cui, 2014, Journal of medicinal chemistry.

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

Weiguo Qing, Meifang Zhang, Y. Sai, 2014, Cancer biology & therapy.

A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.

Jianming Xu, Huichuan Sun, Yi Li, 2021 .

Surufatinib in Chinese patients with locally advanced or metastatic differentiated thyroid cancer and medullary thyroid cancer: A multicenter, open-label, Phase II trial.

Y. Zhang, Xiangqian Zheng, C. Bai, 2020, Thyroid : official journal of the American Thyroid Association.